UnitedHealth Group Faces Significant Challenges Amidst CEO Changes and Investigations

Few stocks have shown resilience like UnitedHealth Group (NYSE: UNH). As the largest health insurance provider in the U.S. and the second-largest pharmacy benefits manager (PBM), the company has also established a rapidly growing healthcare technology and services division with Optum. However, recent developments have sent shares to a five-year low, plummeting over 50% from their peak in late 2024. Here are five key insights for investors.

1. Withdrawal of Financial Guidance

Recently, UnitedHealth Group withdrew its financial guidance for 2025. Initially, it forecasted net earnings ranging from $24.65 to $25.15 per share based on generally accepted accounting principles (GAAP), with adjusted earnings anticipated between $26 and $26.50 per share. This midpoint represented a modest decline of about 5% year over year.

Management cited “heightened care activity indications” in its Medicare Advantage business and unexpected changes in Optum Health members’ characteristics as contributing factors. During the first-quarter update on April 27, 2025, management believed these issues were manageable throughout the year. However, last week, the company stated that medical expenditures are expected to exceed prior estimates, particularly for new Medicare Advantage beneficiaries. Nonetheless, a return to growth is projected for 2026.

2. Leadership Changes

In a critical move, UnitedHealth announced its withdrawn guidance alongside the unexpected departure of CEO Andrew Witty, who left for “personal reasons.” Witty, who had led the company for over four years and previously held positions at UnitedHealth Group and Optum, was replaced immediately by Stephen J. Hemsley. Hemsley, who previously served as CEO from 2006 to 2017, will also continue to chair the board.

3. Department of Justice Investigation

Compounding these challenges, a day after the CEO announcement and guidance withdrawal, The Wall Street Journal reported that the U.S. Department of Justice (DOJ) is investigating UnitedHealth for potential Medicare fraud. Previously, in February 2025, it was disclosed that the DOJ was examining the company’s Medicare billing practices.

In response, UnitedHealth issued a statement clarifying, “We have not been notified by the Department of Justice of the supposed criminal investigation reported… The WSJ’s reporting is deeply irresponsible.” The company reaffirmed its commitment to the integrity of its Medicare Advantage program.

Image source: Getty Images.

4. Pressures on PBM Business

In addition to these issues, UnitedHealth Group’s Optum Rx PBM division faces significant scrutiny. Recently, President Trump announced plans to eliminate PBMs, stating, “We’re going to cut out the middleman and facilitate the direct sale of drugs at the most favored national price.” This aligns with Health and Human Services Secretary Robert F. Kennedy Jr.’s earlier remarks emphasizing the need to tackle PBM profits and redirect funds to primary care and patients.

In the first quarter of 2025, Optum Rx reported over $13.9 billion in revenue, accounting for nearly 13% of UnitedHealth Group’s total revenue. This segment contributed $1.3 billion in earnings before income taxes, representing about 16% of the company’s overall earnings.

5. Analysts Remain Optimistic

Despite these setbacks, Wall Street analysts maintain a largely positive outlook on UnitedHealth Group. Of 27 surveyed analysts by LSEG in May, 22 rated the stock as a “buy” or “strong buy,” with only one “sell” rating. Following the recent developments, several top analysts reiterated their buy recommendations, with an average 12-month price target suggesting an upside potential of approximately 47%.

Concerns regarding the CEO transition are tempered by Hemsley’s experience. The DOJ investigation, while concerning, may not have immediate ramifications. The primary worry lies with Optum Rx, especially amid potential regulatory changes surrounding PBMs. Nevertheless, the negatives appear to be reflected in UnitedHealth’s current share price, which is trading at 11.5 times forward earnings. For risk-tolerant investors, this may present a buying opportunity for the undervalued stock.

Should You Invest $1,000 in UnitedHealth Group Right Now?

Before considering an investment in UnitedHealth Group, it’s vital to evaluate the latest information:

The analyst team at Motley Fool Stock Advisor recently identified ten stocks deemed better investment opportunities, with UnitedHealth Group not making the list. Historical data shows that following their recommendations, notable stocks like Netflix and Nvidia yielded tremendous returns.

Importantly, the performance of Stock Advisor stands at an average return of 975%, significantly outpacing the S&P 500’s 172%. Investors may want to take heed of additional top stock picks.

Keith Speights has no position in any of the mentioned stocks. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.